Corcept Therapeutics (CORT) CFO awarded stock options on 140,000 shares

Rhea-AI Filing Summary

Corcept Therapeutics' Chief Financial Officer receives a new stock option grant. On February 27, 2026, CFO Atabak Mokari was granted stock options covering 140,000 shares of Corcept Therapeutics common stock at an exercise price of $0.00 per share, recorded as a direct ownership position.

The options vest in equal monthly installments over four years, starting from the monthly anniversary of February 27, 2026, and require the executive’s continued service through each vesting date. After this grant, the reported derivative holdings from this award total 140,000 options.

Insights

Equity Compensation Analyst

Routine executive option grant increases equity-based incentives for the CFO.

The filing shows Corcept Therapeutics' CFO received a grant of stock options for 140,000 shares at an exercise price of $0.00 per share. This is classified as a grant or award acquisition, not an open-market purchase, and represents additional derivative-based compensation.

The options vest monthly over four years starting on the monthly anniversary of February 27, 2026, contingent on continued service. This structure encourages ongoing tenure and aligns compensation with long-term performance as value is realized only upon vesting and potential future exercises under the plan’s terms.

The impact depends on future stock performance and whether the options become economically valuable relative to the exercise price. Subsequent company filings may detail aggregate executive equity awards and any exercises that translate these options into common shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mokari Atabak

(Last) (First) (Middle)

C/O CORCEPT THERAPEUTICS INCORPORATED

101 REDWOOD SHORES PARKWAY

(Street)

REDWOOD CITY CA 94065

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$35.7	02/27/2026		A		140,000		(1)	02/27/2036	Common Stock	140,000	$0	140,000	D

Explanation of Responses:

1. Exercise ratably in equal installments on each monthly anniversary of February 27, 2026 over a four-year period subject to the Reporting Person's continued service through each vesting date.

Remarks:

The power of attorney under which this form was signed is on file with the Commission.

	/s/ Joseph Douglas Lyon, as attorney-in-fact for Atabak Mokari.	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Corcept Therapeutics (CORT) disclose about CFO Atabak Mokari in this Form 4?

Corcept Therapeutics reported that CFO Atabak Mokari received a grant of stock options covering 140,000 shares. The options are recorded as directly owned derivative securities and represent equity-based compensation granted on February 27, 2026, rather than an open-market stock purchase or sale.

How many Corcept Therapeutics (CORT) shares are covered by the new option grant to the CFO?

The new stock option award to Corcept’s CFO covers 140,000 shares of common stock. This entire amount is reported as derivative securities following the transaction, reflecting the full size of the grant documented in the Form 4 insider trading report.

What is the exercise price of the Corcept Therapeutics (CORT) stock options granted to the CFO?

The reported exercise price for the CFO’s stock option grant is $0.00 per share. This means the options themselves represent the economic incentive, and any eventual value will depend on the company’s stock performance and the terms of the underlying equity plan.

How do the stock options granted to Corcept Therapeutics (CORT) CFO vest over time?

The options vest ratably in equal installments on each monthly anniversary of February 27, 2026. Vesting continues over a four-year period and is conditioned on the reporting person’s continued service through each vesting date, according to the footnote disclosure in the Form 4.

Is the Corcept Therapeutics (CORT) CFO’s new option grant a direct or indirect holding?

The Form 4 classifies the CFO’s new stock options as a direct ownership interest. The reporting codes indicate direct ownership, and there is no footnote shifting voting or investment authority to another entity such as a trust, partnership, or family-controlled vehicle.

Does this Corcept Therapeutics (CORT) Form 4 reflect a buy or sell of common shares?

No open-market buy or sell of common shares is reported. The transaction is coded as an acquisition via grant of a derivative security, specifically stock options, rather than a purchase or sale of already outstanding Corcept Therapeutics common stock in the market.